Skip to main content
OpenTrials
Completed

NCT Number: NCT01588132

Anfibatide Phase 1 Clinical Trial in Healthy Volunteers

In this 94 healthy subjects Phase I clinical trial, we assess the clinical profile of Anfibatide, a specific glycoprotein Ib antagonist. This study represents the first clinical evidence that Anfibatide exhibits strong anti-platelet effects, excellent reversibility, and low bleeding potential in healthy human subjects.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1) Healthy volunteers, aged 18-28 years, male and female were included, age difference less than 10 years;
  • 2) Body weight: with body mass index (BMI) between 19-24, difference less than 10kg in the same group, BMI=body weight(kg)/height2;
  • 3) Past medical history: no history of heart, liver, kidney, digestive tract, nervous system and metabolic disorder, or ulcer, significant hemorrhage, without the history of drug allergy and postural hypotension;
  • 4) Medical examinations: with normal results in overall examinations (including heart rate, blood pressure, auscultation of heart and lung, palpation of liver and spleen, hepatic and renal function, hematology, coagulation function, urine analysis, stool analysis and occult blood test, electrocardiogram);
  • 5) Have not received any medications within 2 weeks before the study;
  • 6) Willing to participate in the study and give a signed informed consent form after understanding the study procedures and potential adverse reactions of the study product.

Exclusion criteria

  • 1) History of HBV or HCV infection;
  • 2) Addicted to smoking or alcohol;
  • 3) Women during pregnancy, lactation or menstrual period;
  • 4) Past history of hemoptysis, bloody stool, bleeding spots in the skin and mucous membrane, or hemorrhagic tendency (find themselves prone to bleeding in gums, nose, skin and mucous membrane, or hemoptysis);
  • 5) History of active bleeding (such as peptic ulcer, hemorrhoids, active tuberculosis, subacute bacterial endocarditis, etc);
  • 6) Blood platelet count less than 150×109;
  • 7) Trauma history (e.g., craniocerebral trauma) recently;
  • 8) Past history of unexplained syncope or convulsion;
  • 9) History of organic or psychogenic disease or the disabled;
  • 10) Persons who were unlikely to participate in the study (such as the infirm) in the investigator's opinion;
  • 11) Have donated blood or experienced blood collection in other trials within 3 months.

Treatment and study plan

Anfibatide

Drug
  • To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.
  • To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours.

Primary outcomes

  1. Safety endpoints

    Time frame: 24 Hours

    To investigate the number of adverse events in patients with single or multiple intravenous injection/infusion of Antiplatelet

Secondary outcomes

  1. Area Under Curve (AUC)

    Time frame: Predose, 0,1,2,3,4,6,8,12,24,48,72,96 Hours

    To observe area under curve characteristics of Anfibatide in single or multiple dose groups

Sponsors and collaborators

Lead sponsor

Lee's Pharmaceutical Limited

Industry

Registry information

Official study title

First Assessment of the Glycoprotein Ib-IV-V Complex Antagonist Anfibatide in Healthy Human Volunteers

Important dates

Study start
2010
Primary completion
2011
Study completion
2011
First posted
Apr 30, 2012
Registry last updated
Apr 30, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.